Cancer Genetics Buying Indian Firm BioServe for $1.9M; Q1 Revenues up 17 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Cancer Genetics today announced an agreement to buy Indian genomics and next-generation sequencing services firm BioServe Biotechnologies for $1.9 million, primarily in stock and other deferred considerations.

The Rutherford, NJ-based cancer genetics testing firm also reported a 17 percent increase in its first quarter revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.